Journal ArticleDOI
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome
Raphaèle Seror,Philippe Ravaud,Xavier Mariette,Xavier Mariette,Hendrika Bootsma,Elke Theander,Arne Hansen,Manel Ramos-Casals,Thomas Doerner,Stefano Bombardieri,Eric Hachulla,Johan G. Brun,Aike A. Kruize,Sonja Praprotnik,Matija Tomšič,Jacques-Eric Gottenberg,Valérie Devauchelle,Salvatore deVita,C. Vollenweider,Thomas Mandl,Athanasios G. Tzioufas,Steven E. Carsons,Alain Saraux,Nurhan Sutcliffe,Claudio Vitali,Simon J Bowman +25 more
Reads0
Chats0
TLDR
The EULAR SS Patient Reported Index is a very simple index designed to measure patients' symptoms in primary SS and has good construct validity and is well correlated with SSI and PROFAD.Abstract:
Objectives To develop a score for assessment of patients9 symptoms in primary Sjogren9s syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI). Methods Dryness, pain, somatic and mental fatigue were identified as the main symptoms of patients with primary SS, in studies developing the Profile of Fatigue and Discomfort (PROFAD) and Sicca Symptoms Inventory (SSI). It was suspected that a single 0–10 numerical scale for each domain was sufficient to assess these symptoms. These four scales were gathered to form the ESSPRI. 230 patients, from 12 countries completed the ESSPRI, SSI and PROFAD questionnaires and a 0–10 patient global assessment (PGA). Correlations between each symptom and PGA were obtained. Multiple regression modelling, using PGA as ‘gold standard’ was used to select domains and estimate their weights. Results PGA had good correlation with dryness, limb pain, fatigue and mental fatigue (r=0.49–0.59, all p Conclusion ESSPRI is a very simple index designed to measure patients9 symptoms in primary SS. It has good construct validity and is well correlated with SSI and PROFAD. ESSPRI should now be validated for use as an outcome measure in clinical trials.read more
Citations
More filters
Journal ArticleDOI
2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome A consensus and data-driven methodology involving three international patient cohorts
Caroline H. Shiboski,Stephen Shiboski,Raphaèle Seror,Lindsey A. Criswell,M. Labetoulle,Thomas M. Lietman,Astrid Rasmussen,Hal Scofield,Claudio Vitali,Simon J Bowman,Xavier Mariette +10 more
TL;DR: A single set of data-driven consensus classification criteria for primary Sjögren's syndrome performed well in validation analyses and are well suited as criteria for enrolment in clinical trials.
Journal ArticleDOI
2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts
Caroline H. Shiboski,Stephen Shiboski,Raphaèle Seror,Lindsey A. Criswell,M. Labetoulle,Thomas M. Lietman,Astrid Rasmussen,Hal Scofield,Claudio Vitali,Simon J Bowman,Xavier Mariette +10 more
TL;DR: To develop and validate an international set of classification criteria for primary Sjögren's syndrome using guidelines from the American College of Rheumatology and the European League Against Rheumatism.
Journal ArticleDOI
Primary Sjögren’s Syndrome
TL;DR: In the absence of trials involving patients with primary Sjögren's syndrome, severe organ manifestations are treated with immunosuppressive agents (including prednisone, methotrexate, mycophenolate sodium, azathioprine, and cyclophosphamide), in accordance with guidelines for systemic lupus erythematosus and other connective‐tissue diseases.
Journal ArticleDOI
Sjögren syndrome
Pilar Brito-Zerón,W. Baldini,Hendrika Bootsma,Simon J. Bowman,Roland Jonsson,Xavier Mariette,Kathy L. Sivils,Elke Theander,Athanasios G. Tzioufas,Manuel Ramos-Casals +9 more
TL;DR: Knowledge of SjS has progressed substantially, but this disease is still characterized by sicca symptoms, the systemic involvement of disease, lymphocytic infiltration to exocrine glands, the presence of anti-Ro/SSA and anti-La/SSB autoantibodies and the increased risk of lymphoma in patients with SJS.
Journal ArticleDOI
Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study
Xavier Mariette,Raphaèle Seror,Luca Quartuccio,Gabriel Baron,S. Salvin,Martina Fabris,F. Desmoulins,Gaetane Nocturne,Philippe Ravaud,Salvatore De Vita +9 more
TL;DR: Encouraging results justify future randomised controlled trials of belimumab in a selected target population of pSS patients most likely to benefit from treatment.
References
More filters
Journal ArticleDOI
Modified disease activity scores that include twenty-eight-joint counts : development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
M.L.L. Prevoo,M.A. van 't Hof,H.H. Kuper,M.A. van Leeuwen,L. B. A. Van De Putte,P.L.C.M. van Riel +5 more
TL;DR: The Modified DAS that included 28-joint counts were able to discriminate between high and low disease activity (as indicated by clinical decisions of rheumatologists) and are as valid as disease activity scores that include more comprehensive joint counts.
Journal ArticleDOI
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group
Claudio Vitali,Stefano Bombardieri,Roland Jonsson,Haralampos M. Moutsopoulos,E L Alexander,Steven E. Carsons,Troy E. Daniels,P C Fox,Robert I. Fox,Stuart S. Kassan,S R Pillemer,Norman Talal,M H Weisman +12 more
TL;DR: These classification criteria for Sjögren's syndrome have been re-examined by consensus group members, who have introduced some modifications, more clearly defined the rules for classifying patients with primary or secondary SS, and provided more precise exclusion criteria.
Journal ArticleDOI
EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome
Raphaèle Seror,Philippe Ravaud,Simon J Bowman,Gabriel Baron,Athanasios G. Tzioufas,Elke Theander,Jacques-Eric Gottenberg,Hendrika Bootsma,Xavier Mariette,Claudio Vitali +9 more
TL;DR: The ESSDAI is a clinical index designed to measure disease activity in patients with primary Sjögren's syndrome and should facilitate clinical research and be helpful as an outcome measure in clinical trials.
Journal ArticleDOI
Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
J. Pijpe,van Gustaaf Imhoff,Frederik Spijkervet,Jan L. N. Roodenburg,Gerrit Jan Wolbink,K Mansour,Arjan Vissink,Cornelis Kallenberg,Hendrika Bootsma +8 more
TL;DR: Findings of this phase II study suggest that rituximab is effective in the treatment of primary SS and MALT/primary SS and the high incidence of HACAs and associated side effects observed in this study needs further evaluation.
Journal ArticleDOI
Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
Jiska Meijer,Petra M. Meiners,Arjan Vissink,Fred K. L. Spijkervet,Wayel H. Abdulahad,N. Kamminga,Elisabeth Brouwer,Cees G. M. Kallenberg,Hendrika Bootsma +8 more
TL;DR: Rituximab treatment is an effective and safe treatment strategy for patients with primary Sjögren's syndrome and significant improvements were found in comparison with baseline values.
Related Papers (5)
American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort
Stephen Shiboski,Caroline H. Shiboski,Lindsey A. Criswell,Alan N. Baer,Stephen Challacombe,Hector Lanfranchi,Morten Schiødt,Hisanori Umehara,Frederick B. Vivino,Yongju Zhao,Yan Dong,Deborah Greenspan,Ana Maria Heidenreich,Pekka Helin,Bruce Kirkham,Kazuko Kitagawa,Genevieve Larkin,Mengtao Li,Thomas M. Lietman,J Lindegaard,Nancy A. McNamara,Kenneth E. Sack,P. J. Shirlaw,Susumu Sugai,C. Vollenweider,John P. Whitcher,Ava J. Wu,S. Zhang,W Zhang,John S. Greenspan,Troy E. Daniels +30 more